Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer
Earlier Data Showed Better Results For Roche Pairing
Executive Summary
While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.
You may also be interested in...
Six Pivotal Trial Readouts To Look Out For In Q4
With help from Biomedtracker, Scrip takes a look at six drug candidates expecting pivotal data by the end of the year. The assets span a range of therapeutic areas, from ophthalmology to neurology, and are poised to become market firsts, rivals to dominant products or win important label expansions.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.
With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx
While a combo of Cabometyx and Roche’s Tecentriq earlier demonstrated a progression-free survival benefit compared to Nexavar, a subsequent readout showed no overall survival benefit.